PDR5 Antibody

What is PDR5 and what role does it play in yeast?

PDR5 is a plasma membrane ABC transporter that serves as a central element of the pleiotropic drug resistance (PDR) network in Saccharomyces cerevisiae. It functions by actively exporting a wide variety of structurally unrelated compounds from cells, including azoles, ionophores, antibiotics, and other xenobiotics . Unlike many other ABC transporters, PDR5 exhibits constant ATP hydrolysis that is uncoupled from substrate binding, enabling continuous active transport of toxic compounds across the cell membrane .

How does PDR5 differ structurally from other ABC transporters?

PDR5 possesses a distinctive reverse topology compared to other ABC transporters, with nucleotide-binding domains (NBDs) located at the N-terminus of both pseudo-protomers. It also contains a characteristic N-terminal extension of approximately 160-170 amino acids with unknown function . Another unique feature is the linker domain (LD) situated between the two halves of PDR5, composed of two distinct stretches . Additionally, PDR5 exhibits striking degeneration of conserved amino acid residues in its nucleotide binding domains, which affects its functional properties .

What experimental systems are commonly used to study PDR5 function?

The most straightforward methods to analyze PDR5 functionality are drug susceptibility assays on drug agar plates or in liquid culture . These assays typically involve comparing the growth of wildtype cells, PDR5-overexpressing cells, and PDR5-deletion mutants in the presence of known PDR5 substrates such as ketoconazole, fluconazole, cycloheximide, and rhodamine 123 . Plasma membrane preparations can also be used to characterize PDR5-specific ATPase activity, with oligomycin sensitivity used to differentiate PDR5 activity from background ATPase activity .

How can researchers effectively purify and reconstitute PDR5 for structural studies?

For high-resolution structural studies using cryo-electron microscopy (cryo-EM), PDR5 can be reconstituted in peptidiscs, which are short amphipathic bi-helical peptides compatible with single-particle analysis . This approach has successfully revealed the molecular structure of PDR5 and its conformational changes during the transport cycle. The reconstitution process should maintain the protein in a functional state, which can be verified by measuring ATPase activity before and after reconstitution. When designing such experiments, researchers should consider the pH dependency of PDR5 ATPase activity, which peaks over a relatively broad pH range with maximal oligomycin-sensitive activity at approximately pH 9.5 .

What methods can be used to investigate the conformational changes of PDR5 during its transport cycle?

Multiple approaches can be employed to study PDR5 conformational dynamics:

• Structural analysis using cryo-EM of PDR5 trapped in different states of the transport cycle by using ATP analogues or ADP

• Molecular dynamics simulations based on solved structures to predict conformational transitions

• Site-directed spin labeling combined with electron paramagnetic resonance (EPR) spectroscopy

• Fluorescence resonance energy transfer (FRET) between labeled residues to monitor distance changes during the transport cycle

These methods have revealed that PDR5 adopts an inward-facing conformation in its resting state, with the substrate entry channel open toward the cytoplasm and inner leaflet of the membrane . During the transport cycle, one half of the transporter remains nearly invariant while its partner undergoes changes transmitted across inter-domain interfaces, supporting a peristaltic motion of the substrate .

How should researchers approach the analysis of PDR5 mutants to understand structure-function relationships?

When analyzing PDR5 mutants, researchers should implement a multi-faceted approach combining:

• Drug resistance phenotyping using susceptibility assays with multiple substrates to identify substrate-specific effects

• Quantification of protein expression levels through immunoblotting to distinguish between expression and functional defects

• Measurement of ATPase activity using isolated plasma membranes to assess catalytic function

• Substrate transport assays using fluorescent substrates like rhodamine 123 to directly measure efflux activity

• mRNA quantification and stability assays to identify potential effects on transcript regulation

This comprehensive approach has revealed important insights, such as how mutations in the H-loop can selectively affect rhodamine transport while leaving the transport of other substrates unaffected , and how nonsynonymous mutations in an unconserved stretch of amino acids can increase PDR5 expression by enhancing mRNA stability .

How does ATP hydrolysis couple to substrate transport in PDR5?

Unlike mammalian P-glycoprotein (P-gp), PDR5's ATPase activity is not stimulated by substrate addition, indicating that PDR5 functions as an uncoupled ABC transporter that constantly hydrolyzes ATP to drive active substrate transport . This mechanistic difference suggests that PDR5 maintains a constant ATP turnover rate regardless of substrate availability. The transport cycle involves ATP binding to nucleotide binding site 2 (NBS2), while the deviant NBS1 likely maintains ATP bound throughout the cycle under physiological conditions . The ATP-driven conformational cycle mechanically drives drug translocation through an amphipathic channel, with a clamping switch within a conserved linker loop functioning as a nucleotide sensor .

What determines substrate specificity in PDR5, and how can it be experimentally assessed?

Substrate specificity in PDR5 is determined by complex interactions between transmembrane domains and substrates. Contrary to expectations, research has shown that not solely the transmembrane domains dictate substrate selection; the nucleotide binding domains also contribute to substrate specificity .

To experimentally assess substrate specificity, researchers can:

• Perform competitive transport assays with fluorescent substrates like rhodamine 123 in the presence of non-fluorescent test compounds

• Use site-directed mutagenesis targeting specific residues in transmembrane helices followed by transport assays with diverse substrates

• Conduct docking simulations based on solved structures to predict binding sites

• Employ photoaffinity labeling with substrate analogues to identify residues directly involved in substrate binding

These approaches can reveal substrate-specific interactions, such as those observed with mutations in the H-loop that specifically affect rhodamine transport .

How do mutations in PDR5 coding regions affect mRNA stability and expression levels?

Recent research has revealed that nonsynonymous mutations in an unconserved stretch of amino acids in the Linker-2 region of PDR5 can increase its expression, enhancing multidrug resistance . These mutations specifically increase the half-life of PDR5 transcripts, as demonstrated through metabolic labeling of mRNA with 4-thiouracil followed by uracil chasing . This suggests that PDR5 has a previously undiscovered RNA stability element within its coding region.

When investigating such phenomena, researchers should implement:

• Quantitative RT-PCR to measure transcript levels

• Cycloheximide chase experiments to rule out changes in protein stability

• mRNA half-life measurements using metabolic labeling or transcription inhibitors

• Protein expression analysis via western blotting

These findings highlight that nucleotides encoding even unconserved amino acids may be used to regulate expression, adding complexity to structure-function analyses .

What techniques can be used to study the bidirectional PDR5 promoter and its role in drug resistance?

The PDR5 promoter acts bidirectionally, controlling not only PDR5 expression but also the expression of YOR152C, which may contribute to drug resistance . To study this complex promoter:

• Construct reporter gene fusions in both orientations to measure promoter activity

• Perform chromatin immunoprecipitation (ChIP) to identify transcription factors binding to the promoter

• Use deletion analysis to map essential promoter elements

• Conduct electrophoretic mobility shift assays (EMSA) to confirm protein-DNA interactions

• Compare drug resistance phenotypes of strains with deletions of the promoter, PDR5, or both

Such approaches have shown that cells lacking both the PDR5 promoter and PDR5 exhibit greater resistance to fluconazole and rhodamine 123 compared to cells lacking only PDR5, indicating that the promoter's bidirectional activity contributes to the complex regulation of drug resistance .

How can research on yeast PDR5 inform studies of drug resistance in pathogenic fungi?

Research on PDR5 in Saccharomyces cerevisiae provides valuable insights for understanding drug resistance in pathogenic fungi, particularly because PDR5 homologs (like Cdr1) in Candida albicans contribute to azole resistance in opportunistic fungal pathogens affecting immunocompromised patients . Comparative studies should:

• Identify conserved functional domains between PDR5 and its pathogenic homologs

• Determine whether mechanistic principles of transport and regulation are conserved

• Test whether inhibitors developed against PDR5 are effective against its homologs

• Compare substrate specificity profiles to identify common or divergent features

The recent structural characterization of PDR5 opens new avenues for the development of effective antifungal compounds that could target PDR transporters in pathogenic species .

What are the key differences between yeast PDR5 and mammalian P-glycoprotein that impact experimental design?

Several crucial differences between PDR5 and mammalian P-glycoprotein (P-gp) must be considered when designing experiments:

• PDR5 exhibits uncoupled ATPase activity that is not stimulated by substrates, unlike P-gp where substrates enhance ATP hydrolysis

• PDR5 has a reverse topology compared to P-gp, with NBDs at the N-terminus of both pseudoprotomers

• PDR5 contains degenerate nucleotide binding sites, with one site (NBS1) being catalytically inactive under physiological conditions

• The substrate specificity profiles differ, though there is some overlap

These differences impact experimental approaches, particularly when screening for inhibitors or studying the coupling between ATP hydrolysis and transport. They also suggest that drug development strategies targeting ABC transporters may need to be tailored specifically for fungal versus mammalian transporters.